Clarivate to Sell Life Sciences Unit in $600 Million Asset Deal
The divestiture sharpens Clarivate’s focus on AI-driven intelligence for academia and intellectual property, the company said.
**Clarivate Plc (CLVT) agreed to sell its Life Sciences & Healthcare segment in a $600 million asset-purchase transaction**, the company said Monday, marking a decisive step in its portfolio rationalization.
The deal, expected to close by year-end, is subject to customary closing conditions, including regulatory approvals and the expiration of applicable waiting periods. Clarivate did not disclose the buyer or any premium to recent trading levels.
**The divestiture aligns with Clarivate’s four-pillared Value Creation Plan**, which targets business-model optimization, improved sales execution, accelerated innovation, and portfolio rationalization. By exiting the Life Sciences & Healthcare segment, Clarivate said it will sharpen its focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments, enhancing its financial profile through an improved revenue mix, expanded Adjusted EBITDA margin, and lower capital intensity.
Matti Shem Tov, Chief Executive Officer of Clarivate, said: *'We are pleased to have reached this agreement, which is well-aligned with Clarivate's four-pillared Value Creation Plan to optimize our business model, improve our sales execution, accelerate innovation and rationalize our portfolio, all with the goal of unlocking shareholder value. With the complementary nature of A&G’s and IP’s businesses, we will enhance efficiency, sharpen execution, strengthen innovation and grow customer reach'*.
**The Life Sciences & Healthcare segment**, which provides commercial analytics, drug safety intelligence, and regulatory solutions to pharmaceutical and biotech companies, had been under strategic review since early 2026. Clarivate had previously flagged the unit as non-core to its long-term vision, which centers on proprietary intelligence amplified by AI across mission-critical workflows in academia and intellectual property. The segment’s recurring revenue mix had improved in recent quarters, but management had cited the need to concentrate resources on higher-growth, higher-margin areas.
**The sale follows a pattern of portfolio pruning among information-services providers** seeking to streamline operations and redirect capital toward AI-driven growth. Earlier this year, Clarivate itself had signaled its intent to divest the Life Sciences & Healthcare business, noting that multiple parties were conducting due diligence. The $600 million valuation reflects a strategic exit from a segment that, while profitable, did not align with the company’s core focus on subscription-based, AI-enabled intelligence solutions.
**Regulatory approvals and the expiration of antitrust waiting periods remain key conditions** for closing, the company said. Clarivate expects the transaction to be accretive to Adjusted EBITDA margins and free cash flow conversion, supporting its commitment to disciplined capital allocation and shareholder returns. The company has not disclosed specific synergy targets but has emphasized that the divestiture will allow it to reinvest in its higher-margin Academia & Government and Intellectual Property segments, where it sees stronger growth potential driven by AI adoption and subscription transitions.